LUNA-18
- Generic Name
- LUNA-18
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 195
- Registration Number
- NCT05012618
- Locations
- 🇺🇸
University of California - Davis, Davis, California, United States
🇺🇸Beth Israel Deaconess, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath